• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

特发性肺纤维化的流行病学研究:方法学与数据解读中的陷阱

Epidemiological studies in idiopathic pulmonary fibrosis: pitfalls in methodologies and data interpretation.

作者信息

Caminati Antonella, Madotto Fabiana, Cesana Giancarlo, Conti Sara, Harari Sergio

机构信息

U.O. di Pneumologia e Terapia Semi-Intensiva Respiratoria - Servizio di Fisiopatologia Respiratoria ed Emodinamica Polmonare, Ospedale San Giuseppe - Multimedica IRCCS, Milan, Italy Both authors contributed equally

Research Center on Public Health, Dept of Health Science, University of Milano-Bicocca, Monza, Italy Both authors contributed equally.

出版信息

Eur Respir Rev. 2015 Sep;24(137):436-44. doi: 10.1183/16000617.0040-2015.

DOI:10.1183/16000617.0040-2015
PMID:26324805
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9487686/
Abstract

Data on incidence, prevalence and mortality of idiopathic pulmonary fibrosis (IPF) are sparse and vary across studies. The true incidence and prevalence of the disease are unknown. In general, the overall prevalence and incidence reported in European and Asian countries are lower than those reported in American studies. In recent years, the epidemiological approach to IPF has been difficult for many reasons. First, the diagnostic criteria of the disease have changed over time. Secondly, the coding system used for IPF in administrative databases, the most common data source used to study this aspect of the disease, has been modified in the past few years. Finally, the study design, the methodology and the population selected in each of the studies are very different. All these aspects make comparisons among studies very difficult or impossible. In this review, we list the main issues that might arise when comparing different studies and that should be taken into consideration when describing the state of epidemiological knowledge concerning this pathology.

摘要

关于特发性肺纤维化(IPF)的发病率、患病率和死亡率的数据稀少,且各研究结果存在差异。该病的真实发病率和患病率尚不清楚。总体而言,欧洲和亚洲国家报告的总体患病率和发病率低于美国研究报告的数据。近年来,由于多种原因,IPF的流行病学研究方法面临困难。首先,该疾病的诊断标准随时间发生了变化。其次,行政数据库中用于IPF的编码系统(研究该疾病这一方面最常用的数据源)在过去几年中已被修改。最后,每项研究的研究设计、方法和所选人群差异很大。所有这些因素使得不同研究之间的比较非常困难甚至无法进行。在本综述中,我们列出了比较不同研究时可能出现的主要问题,以及在描述有关这种病理学的流行病学知识状况时应考虑的问题。

相似文献

1
Epidemiological studies in idiopathic pulmonary fibrosis: pitfalls in methodologies and data interpretation.特发性肺纤维化的流行病学研究:方法学与数据解读中的陷阱
Eur Respir Rev. 2015 Sep;24(137):436-44. doi: 10.1183/16000617.0040-2015.
2
Code-based Diagnostic Algorithms for Idiopathic Pulmonary Fibrosis. Case Validation and Improvement.基于代码的特发性肺纤维化诊断算法。病例验证和改进。
Ann Am Thorac Soc. 2017 Jun;14(6):880-887. doi: 10.1513/AnnalsATS.201610-764OC.
3
Idiopathic pulmonary fibrosis: diagnosis and epidemiology.特发性肺纤维化:诊断与流行病学。
Clin Chest Med. 2012 Mar;33(1):41-50. doi: 10.1016/j.ccm.2011.12.001.
4
Idiopathic pulmonary fibrosis--a systematic review on methodology for the collection of epidemiological data.特发性肺纤维化--流行病学数据收集方法的系统评价。
BMC Pulm Med. 2013 Aug 20;13:53. doi: 10.1186/1471-2466-13-53.
5
Incidence and prevalence of idiopathic interstitial pneumonia and idiopathic pulmonary fibrosis in Korea.韩国特发性间质性肺炎和特发性肺纤维化的发病率及患病率。
Int J Tuberc Lung Dis. 2016 Jul;20(7):978-84. doi: 10.5588/ijtld.16.0003.
6
Global incidence and prevalence of idiopathic pulmonary fibrosis.特发性肺纤维化的全球发病率和患病率。
Respir Res. 2021 Jul 7;22(1):197. doi: 10.1186/s12931-021-01791-z.
7
Idiopathic Pulmonary Fibrosis (IPF) incidence and prevalence in Italy.意大利特发性肺纤维化(IPF)的发病率和患病率。
Sarcoidosis Vasc Diffuse Lung Dis. 2014 Oct 20;31(3):191-7.
8
Incidence and prevalence of idiopathic pulmonary fibrosis in US adults 18-64 years old.美国 18-64 岁成年人特发性肺纤维化的发病率和患病率。
Eur Respir J. 2016 Jul;48(1):179-86. doi: 10.1183/13993003.01653-2015. Epub 2016 Apr 28.
9
Characterizing Health Outcomes in Idiopathic Pulmonary Fibrosis using US Health Claims Data.利用美国健康索赔数据描述特发性肺纤维化的健康结局。
Respiration. 2020;99(2):108-118. doi: 10.1159/000504630. Epub 2020 Jan 24.
10
Epidemiology of idiopathic pulmonary fibrosis: a population-based study in primary care.特发性肺纤维化的流行病学:初级保健中的一项基于人群的研究。
Intern Emerg Med. 2020 Apr;15(3):437-445. doi: 10.1007/s11739-019-02195-0. Epub 2019 Sep 20.

引用本文的文献

1
Lysionotin attenuates bleomycin-induced pulmonary fibrosis by activating AMPK/Nrf2 pathway.赖索西汀通过激活AMPK/Nrf2通路减轻博来霉素诱导的肺纤维化。
Sci Rep. 2025 Aug 25;15(1):31306. doi: 10.1038/s41598-025-17045-7.
2
Shifting Trends in the Epidemiology and Management of Idiopathic Pulmonary Fibrosis in the Era of Evidence-Based Guidelines: a Nationwide Population Study.循证指南时代特发性肺纤维化流行病学和管理的变化趋势:一项全国性人群研究
J Epidemiol Glob Health. 2025 Mar 17;15(1):44. doi: 10.1007/s44197-025-00377-y.
3
Cellular therapies for idiopathic pulmonary fibrosis: current progress and future prospects.特发性肺纤维化的细胞疗法:当前进展与未来前景
Am J Stem Cells. 2024 Aug 25;13(4):191-211. doi: 10.62347/DAKS5508. eCollection 2024.
4
Mechanical ventilation in patients with idiopathic pulmonary fibrosis in Korea: a nationwide cohort study.韩国特发性肺纤维化患者的机械通气:一项全国性队列研究。
Korean J Intern Med. 2024 Mar;39(2):295-305. doi: 10.3904/kjim.2023.273. Epub 2024 Feb 8.
5
Chronic pulmonary fibrosis alters the functioning of the respiratory neural network.慢性肺纤维化会改变呼吸神经网络的功能。
Front Physiol. 2023 Jun 13;14:1205924. doi: 10.3389/fphys.2023.1205924. eCollection 2023.
6
Nanotherapeutic Approaches to Treat COVID-19-Induced Pulmonary Fibrosis.治疗新冠病毒诱导的肺纤维化的纳米治疗方法。
BioTech (Basel). 2023 May 5;12(2):34. doi: 10.3390/biotech12020034.
7
Comorbidity burden and survival in patients with idiopathic pulmonary fibrosis: the EMPIRE registry study.特发性肺纤维化患者的合并症负担和生存:EMPIRE 登记研究。
Respir Res. 2022 May 27;23(1):135. doi: 10.1186/s12931-022-02033-6.
8
Occurrence of Idiopathic Pulmonary Fibrosis in Italy: Latest Evidence from Real-World Data.意大利特发性肺纤维化的发病情况:真实世界数据的最新证据。
Int J Environ Res Public Health. 2022 Feb 22;19(5):2510. doi: 10.3390/ijerph19052510.
9
Sex Differences in the Incidence and Outcomes of Patients Hospitalized by Idiopathic Pulmonary Fibrosis (IPF) in Spain from 2016 to 2019.2016年至2019年西班牙特发性肺纤维化(IPF)住院患者的发病率及预后的性别差异
J Clin Med. 2021 Aug 6;10(16):3474. doi: 10.3390/jcm10163474.
10
All-cause mortality of patients with idiopathic pulmonary fibrosis: a nationwide population-based cohort study in Korea.特发性肺纤维化患者的全因死亡率:韩国全国基于人群的队列研究。
Sci Rep. 2021 Jul 26;11(1):15145. doi: 10.1038/s41598-021-94655-x.

本文引用的文献

1
Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review.特发性肺纤维化的全球发病率和死亡率:系统评价。
Eur Respir J. 2015 Sep;46(3):795-806. doi: 10.1183/09031936.00185114. Epub 2015 May 14.
2
Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry.临床实践中特发性肺纤维化患者的管理:INSIGHTS-IPF注册研究
Eur Respir J. 2015 Jul;46(1):186-96. doi: 10.1183/09031936.00217614. Epub 2015 Apr 2.
3
Idiopathic Pulmonary Fibrosis (IPF) incidence and prevalence in Italy.意大利特发性肺纤维化(IPF)的发病率和患病率。
Sarcoidosis Vasc Diffuse Lung Dis. 2014 Oct 20;31(3):191-7.
4
Increasing global mortality from idiopathic pulmonary fibrosis in the twenty-first century.21世纪特发性肺纤维化导致的全球死亡率不断上升。
Ann Am Thorac Soc. 2014 Oct;11(8):1176-85. doi: 10.1513/AnnalsATS.201404-145OC.
5
Epidemiologic survey of Japanese patients with idiopathic pulmonary fibrosis and investigation of ethnic differences.特发性肺纤维化日本患者的流行病学调查及人种差异研究。
Am J Respir Crit Care Med. 2014 Oct 1;190(7):773-9. doi: 10.1164/rccm.201403-0566OC.
6
Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001-11.美国 65 岁及以上医疗保险受益人群中的特发性肺纤维化:2001-2011 年的发病率、患病率和生存率。
Lancet Respir Med. 2014 Jul;2(7):566-72. doi: 10.1016/S2213-2600(14)70101-8. Epub 2014 May 27.
7
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.吡非尼酮治疗特发性肺纤维化患者的 3 期临床试验。
N Engl J Med. 2014 May 29;370(22):2083-92. doi: 10.1056/NEJMoa1402582. Epub 2014 May 18.
8
Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.尼达尼布治疗特发性肺纤维化的疗效和安全性。
N Engl J Med. 2014 May 29;370(22):2071-82. doi: 10.1056/NEJMoa1402584. Epub 2014 May 18.
9
A cohort study of interstitial lung diseases in central Denmark.丹麦中部间质性肺疾病的队列研究。
Respir Med. 2014 May;108(5):793-9. doi: 10.1016/j.rmed.2013.09.002. Epub 2013 Sep 20.
10
Idiopathic pulmonary fibrosis--a systematic review on methodology for the collection of epidemiological data.特发性肺纤维化--流行病学数据收集方法的系统评价。
BMC Pulm Med. 2013 Aug 20;13:53. doi: 10.1186/1471-2466-13-53.